Bloomberg Law  |  November 9, 2023

“It is likely courts will need to directly consider the potential entrance of new biosimilars to drugs selected for negotiation, such as Stelara, when challengers attempt to specifically identify potential financial harm caused by that drug’s inclusion in the negotiation program,” said Zachary Baron, associate director of the Health Policy and the Law Initiative at Georgetown’s O’Neill Institute.

Read more here.